It is well known that proteinases and their natural inhibitors regulate biological functions cooperatively to maintain homeostasis, while any imbalance between proteinases and their natural inhibitors can cause serious disorders.
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With regard to plasmin (PL), a 2 -macroglobulin (a 2 -M) 4 ) and a 2 -plasmin inhibitor (a 2 -PI) 5) are known as endogenous inhibitors. It is also well known that a 2 -PI consists of two parts: one part binds to the active site (catalytic site) of PL and another to the lysine binding site (LBS) of PL. An imbalance between PL and its natural inhibitors causes a serious syndrome, such as hyperfibrinolysis. [6] [7] [8] At present, e-aminocaproic acid 9) and trans-4-aminomethylcyclohexanecarboxylic acid (trans-AMCHA) 10) are used clinically as PL inhibitors. These inhibitors show fairly potent inhibition of fibrinolysis by PL with an IC 50 value of 60 mM, but poor inhibition of the amidolysis of small peptide substrates and fibrinogenolysis by PL. This is because these inhibitors act on PL by blocking the LBS of an enzyme, which is not the catalytic site. 11) With the objectives of obtaining a powerful new tool to study the role of PL and developing novel types of clinical therapy, we focused our attention on the synthesis of potent active center-directed PL inhibitors. Previously, we reported the development of active center-directed inhibitors of PL 12, 13) and studies of their structure-inhibitory activity relationship. 14) Our inhibitors consist of three parts, P 1 , P 1Ј and P 2Ј 15) and their structure-activity relationship is summarized in Table 1 .
As shown in Table 1 , compound I inhibits plasma kallikrein (PK) specifically, compound II inhibits both PL and PK, and compound III inhibits PL specifically. These results, showed that we could design enzyme-selective inhibitors by combining various kinds of substituents at positions P 1 , P 1Ј and P 2Ј .
Bearing in mind the above results, we designed and synthesized a series of plasmin-selective inhibitors and this report deals with these PL inhibitors and their structure-activity relationship.
Tyr(O-2-BrZ) was selected as the P 1Ј substituent, since it is known that this residue can increase the affinity for some part of the active center of trypsin-like proteinases. 14) As the P 1 substituent, we chose 6-aminohexanoic acid or trans-4-aminomethylcyclohexanecarboxylic acid.
First of all, alkyl amines with various chain lengths were used as the P 2Ј substituent. As illustrated in Chart 1, BocTyr(O-2-BrZ)-OH was coupled with alkylamine to give BocTyr(O-2-BrZ)-NH-R (R: n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, 3-methylbutyl, 1,1-dimethylpropyl). After removal of Boc with HCl-dioxane, the resulting amine was coupled with Boc-EACA-OH or Boc-Tra-OH to give Boc-EACA-or Boc-Tra-Tyr(O-2-BrZ)-NH-R, which were treated with 6 N HCl-dioxane to give compounds 1-14. Their inhibitory activities against a series of enzymes are summarized in Table  2 . As the P 1 substituent, the Tra group is more suitable than a) Value in parenthesis are % inhibition at the concentration described (mM).
Development of Plasmin-Selective Inhibitors and Studies of Their
the EACA group as far as potent inhibitory activity is concerned, while the EACA group increased the difference in inhibitory activity between PL and the other enzymes examined so far. As far as the P 2Ј substituent is concerned, increasing the chain length resulted in increased inhibitory activity against PL and reduced inhibitory activity against PK. Compounds 11, 12 inhibited PL potently and selectively. Previously, it was reported that 6-amidino-2-naphthyl p-guanidinobenzoate dimethanesulfonate (FUT-175) inhibited PL, PK and thrombin (TH) with IC 50 values of 0.12, 1.9 and 3.9 mM
(substrate: N a -tosylarginine methyl ester, TAME), respectively. 16) Our compounds contain an amide bond, while FUT-175 contains an ester structure and our compounds exhibited much weaker inhibition of TH compared with FUT-175.
Since compound II in Table 1 inhibited both PL and PK potently, the 4-acetyl group at the P 2Ј position was exchanged for alkyl groups of various chain lengths. As summarized in Table 3 , the inhibitory activity of compounds 15-18 was less than that of compounds 19-22. Compound 19-22 exhibited similar inhibitory activity against PL and trypsin (TRY). The longer the chain length, the weaker the inhibition of PK, although the differences were not very marked. Next, methylene groups were inserted between NH and the aromatic ring of the P 2Ј moiety. As summarized in Table 4 , compound 23 inhibited both PL and PK potently, while insertion of methylene groups reduced the inhibition of PK more than that of PL.
Finally, as the P 2Ј moiety, trans-4-aminomethylcyclohexanecarboxylic acid alkyl esters of various chain lengths were used because we believed that the bulkiness of the cleft and stereogeometry of the active site of PL and PK were quite different. Compounds 27-34 were prepared and their in- hibitory activities are summarized in Table 5 . The inhibitory activity against PL is more potent than against PK, presumably due to the bulkiness of the P 2Ј moiety.
In conclusion, it was found that the cleft of the active center of PL is larger than that of PK and other enzymes and that the compound 11 interacts with the active center of PL, as shown in Fig. 1 . For the further study of PL selective inhibitors, the compound 11 was selected as the lead compound.
Experimental
Melting points were determined on a Yanagimoto micro-melting point apparatus without correction. Optical rotations were measured with an automatic polarimeter, model DIP-360 (Japan Spectroscopic Co. General Procedure for Synthesis of Boc-Tyr(O-2-BrZ)-NH-X [X: npentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, 3-methylbutyl, 1,1-dimethylpropyl] A mixed anhydride of Boc-Tyr(O-2-BrZ)-OH [prepared routinely from Boc-Tyr(O-2-BrZ)-OH (1.5 g, 3.0 mmol), isobutyl chloroformate (0.45 ml, 3.0 mmol) and Et 3 N (0.45 ml, 3.0 mmol)] in tetrahydrofuran (THF, 15 ml) was added to a solution of NH 2 X (X: n-pentyl, n-hexyl, n-heptyl, noctyl, n-nonyl, 3-methylbutyl, 1,1-dimethylpropyl) (3.3 mmol) in THF (10 ml). The reaction mixture was stirred at 4°C overnight. After removal of the solvent, the residue was extracted with AcOEt. The extract was washed with 10% citric acid, 5% Na 2 CO 3 and water, dried over Na 2 SO 4 and evaporated to dryness. Ether was added to the residue to afford crystals, which were collected by filtration. Table 6 .
General Table 7 .
General Procedure for Synthesis of H-EACA-Tyr(O-2-BrZ)-NH-
was dissolved in 5.4 N HCl-dioxane (0.5 ml, 2.7 mmol) at 0°C and the reaction mixture was stirred at the same temperature for 5 min. After addition of dioxane (0.2 ml), the reaction mixture was stirred at room temperature for 90 min. After removal of the solvent, dry ether was added to the residue to afford a precipitate. The yield, mp, [a] D 25 values, elemental analysis and Rf values are summarized in Table 8 .
General Table 9 .
General Procedure for Synthesis of H-Tra-Tyr(O-2-BrZ)-NH-X · HCl (8-14)
[X: n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, 3-methylbutyl, 1,1-dimethylpropyl] Boc-Tra-Tyr(O-2-BrZ)-NH-X [X: n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, 3-methylbutyl, 1,1-dimethylpropyl; (0.14 mmol)] was dissolved in 5.4 N HCl-dioxane (0.5 ml, 2.7 mmol) at 0°C and the reaction mixture was stirred at the same temperature for 5 min. After addition of dioxane (0.2 ml), the reaction mixture was stirred at room temperature for 90 min. After removal of the solvent, dry ether was added to the residue to afford a precipitate. values are summarized in Table 10 . 5 g, 3 .0 mmol), isobutyl chloroformate (0.45 ml, 3.0 mmol) and Et 3 N (0.45 ml, 3.0 mmol)] in THF (15 ml) was added to a solution of NH 2 --X (X: ethyl, n-butyl, npentyl, n-hexyl) (3.3 mmol) in THF (10 ml). The reaction mixture was stirred at 4°C overnight. After removal of the solvent, the residue was extracted with AcOEt. The extract was washed with 10% citric acid, 5% Na 2 CO 3 and water, dried over Na 2 SO 4 and evaporated to dryness. Ether was added to the residue to afford crystals, which were collected by filtration. Table 11 .
General Table 12 . was dissolved in 5.4 N HCl-dioxane (0.5 ml, 2.7 mmol) at 0°C and the reaction mixture was stirred at the same temperature for 5 min. After addition of dioxane (0.2 ml), the reaction mixture was stirred at room temperature for 90 min. After removal of the solvent, dry ether was added to the residue to afford a precipitate. The yield, mp, [a] D 25 values, elemental analysis and Rf values are summarized in Table 13 .
General Procedure for Synthesis of H-EACA-Tyr(O-2-BrZ)-NH--
General 5 g, 3 .0 mmol), isobutyl chloroformate (0.45 ml, 3.0 mmol) and Et 3 N (0.45 ml, 3.0 mmol)] in THF (15 ml) was added to a solution of NH 2 -X (X: 4-pyridyl, 4-picolyl, 2-(2-pyridyl)ethyl, b-phenethyl) (3.3 mmol) in THF (10 ml). The reaction mixture was stirred at 4°C overnight. After removal of the solvent, the residue was extracted with AcOEt. The extract was washed with 10% citric acid, 5% Na 2 CO 3 and water, dried over Na 2 SO 4 and evaporated to dryness. Ether was added to the residue to afford crystals, which were collected by filtration. Table 16 . 4-pyridyl, 4-picolyl, 2-(2-pyridyl) Table 18 .
General Procedure for Synthesis of Boc-Tra-Tyr(O-2-BrZ)-NH-X [X:
General in THF (15 ml) was added to a solution of NH 2 -X (X: methyl, n-hexyl, n-heptyl, n-octyl) (3.3 mmol) in THF (10 ml). The reaction mixture was stirred at 4°C overnight. After removal of the solvent, the residue was extracted with AcOEt. The extract was washed with 10% citric acid, 5% Na 2 CO 3 and water, dried over Na 2 SO 4 and evaporated to dryness. Ether was added to the residue to afford crystals, which were collected by filtration. Table 20 . Table 23 .
Assay Procedure The enzymes used were as follows: human PL and PK (KABI Co.), bovine TH (Mochida Seiyaku Co.), porcine glandular kallikrein (GK) (Sigma Chemical Co.), human urokinase (UK) (Green Cross) and TRY (Sigma Chemical Co.). Enzymatic activities of PL, PK, TH, GK, UK and TRY were determined by the method described previously, 17) 192
Vol. 48, No. 2 ; the IC 50 value was taken as the concentration of inhibitor which reduced the absorbance at 405 nm by 50% compared with the absorbance measured under the same conditions without inhibitor. 2) Antifibrinolytic assay 18) ; the IC 50 value was taken as the concentration of inhibitor which prolonged the complete lysis time two-fold compared with that without inhibitor. 3) Antifibrinogenolytic assay: to a borate saline buffer (pH 7.4) was added solutions containing various concentrations of the inhibitor to be tested (0.5 ml), 0.2% bovine fibrinogen in the above buffer (0.4 ml), and bovine TH 4 U/ml (0.1 ml). The assay was carried out at 37°C and the clotting time was measured. The IC 50 value was taken as the concentration of inhibitor which prolonged the clotting time two-fold compared with that without inhibitor. 
